Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen and Epoch Biosciences to Merge

NEW YORK, Sept. 7 (GenomeWeb News) - Nanogen and Epoch Biosciences have agreed to merge in an all-stock transaction, the companies said today.

 

Under the terms of the agreement, Nanogen has agreed to an offer price of $2 per Epoch share, which is a 30 percent premium over the average closing price of Epoch's shares for the 20 trading days ended Sept. 1, the companies said. Epoch shareholders will receive a number of Nanogen shares based on an exchange ratio determined by dividing the offer price by Nanogen's issue price as calculated at closing.

 

The directors of both companies have signed an agreement to vote in favor of the transaction, which, subject to approval by stockholders is expected to close by the end of this year.

 

Nanogen and Epoch have several complementary products in the molecular diagnostics field, the companies said. Specifically, Epoch's MGB Eclipse Probe System, including recently launched analyte-specific detection reagents, complement Nanogen's NanoChip molecular biology workstation. Both products are used for analyzing gene expression in vitro, detecting SNPs and mutations, and identifying infectious organisms, the companies said.

 

Nanogen said it intends to retain Epoch's R&D capabilities and reagent manufacturing operations in Bothell, Washington. Administration, marketing, and sales will be merged into Nanogen's San Diegoheadquarters.

 

Seven Hills Partners acted as financial advisor to Nanogen in the transaction, while Molecular Securities advised Epoch on the deal.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.